Screener
Monopar Therapeutics MNPR Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 5,225,253 | 3,221,817 |
| Income (loss) from operations | (5,225,253) | (3,221,817) |
| Interest income (loss) | 1,332,203 | 596,845 |
| Net income (loss) | (3,893,050) | (2,624,972) |
| Other comprehensive income (loss): | ||
| Foreign currency translation gain (loss), net | (190) | 1,239 |
| Unrealized gain (loss) on investments, net | (32,678) | 346 |
| Comprehensive income (loss) | $(3,925,918) | $(2,623,387) |
Document
FAQ
- What is Monopar Therapeutics's net income?
- Monopar Therapeutics (MNPR) reported net income of -$3.89M in Q1 2026.
- How has Monopar Therapeutics's net income changed year-over-year?
- Monopar Therapeutics's net income decreased by 48.3% year-over-year, from -$2.62M to -$3.89M.
- What is the long-term trend for Monopar Therapeutics's net income?
- Over 4 years (2021 to 2025), Monopar Therapeutics's net income has grown at a 10.8% compound annual growth rate (CAGR), from -$9.1M to -$13.72M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Monopar Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude